STAT+: In earnings call, Hims CEO addresses scrutiny of G...

What’s Happening

Real talk: In earnings call, Hims Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.

Pharmalot Pharmalot STAT Plus: Bayer sues J&J over false and misleading claims about competing prostate cancer treatments By Ed Silverman Biotech Biotech STAT Plus: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications By Jason Mast and Lizzy Lawrence Health Care Inc. (plot twist fr)

STAT Plus: Medicare’s AI ‘modernization’ project, and the Ohio hospital antitrust battle By Bob Herman Politics Politics Ralph Abraham, No.

Why This Matters

This is the kind of health news that affects everyday decisions.

Health experts are weighing in on what this means for people.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

Is this a W or an L? You decide.